|1.||Azuma, Arata: 13 articles (11/2015 - 01/2005)|
|2.||Margolin, Solomon B: 13 articles (08/2009 - 02/2002)|
|3.||Ogura, Takashi: 8 articles (11/2015 - 01/2011)|
|4.||Suga, Moritaka: 7 articles (11/2015 - 05/2005)|
|5.||Nukiwa, Toshihiro: 6 articles (11/2015 - 05/2005)|
|6.||Kudoh, Shoji: 6 articles (11/2015 - 05/2005)|
|7.||Taniguchi, Hiroyuki: 6 articles (11/2015 - 01/2011)|
|8.||King, Talmadge E: 6 articles (07/2015 - 05/2011)|
|9.||Armendáriz-Borunda, Juan: 6 articles (06/2015 - 01/2008)|
|10.||Oku, Hisashi: 6 articles (01/2012 - 06/2002)|
01/01/2010 - "Although the optimum treatment for fibrosis remains undefined, it is possible that combined therapeutic regimens that include this wide-application molecule, pirfenidone, could offer a useful treatment for fibrotic disease."
01/01/2013 - "Improved mitochondrial function underlies the protective effect of pirfenidone against tubulointerstitial fibrosis in 5/6 nephrectomized rats."
01/01/2006 - "Pirfenidone, a novel compound with documented anti-inflammatory, antioxidant and antifibrotic effects, appears to hold promise in delaying or preventing fibrosis. "
03/10/2010 - "In a histological study, pirfenidone improved interstitial fibrosis in the renal cortex. "
05/01/2015 - "To evaluate the safety and efficacy of Pirfenidone (PFD) in the treatment of equine corneal fibrosis using an in vitro model. "
|2.||Idiopathic Pulmonary Fibrosis
01/01/2014 - "Pirfenidone is a new antifibrotic drug, which has been proven beneficial in idiopathic pulmonary fibrosis and is able to inhibit or reverse BIP in animal models. "
01/01/2011 - "A phase III trial in Japan showed that pirfenidone is effective for idiopathic pulmonary fibrosis (IPF). "
01/01/2015 - "Pirfenidone targets the myofibroblast and is effective in the treatment of idiopathic pulmonary fibrosis. "
06/01/2011 - "As a novel treatment option for idiopathic pulmonary fibrosis (IPF), pirfenidone has been granted marketing authorization in the European Union for the treatment of mild to moderate IPF. "
11/01/2015 - "Efficacy of pirfenidone and disease severity of idiopathic pulmonary fibrosis: Extended analysis of phase III trial in Japan."
|3.||Pulmonary Fibrosis (Hamman Rich Syndrome)
06/01/2005 - "Pirfenidone is an investigational anti-fibrotic agent shown to be effective in blocking pulmonary fibrosis. "
06/01/2011 - "The current, randomized, placebo-controlled, prospective, double-blind trial investigated the safety and efficacy of pirfenidone for mild to moderate HPS-1 and 4 pulmonary fibrosis. "
01/01/2012 - "Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials."
07/01/2014 - "Pirfenidone is an antifibrotic agent for patients with pulmonary fibrosis, but this drug has adverse gastrointestinal (GI) effects. "
01/01/2014 - "CT can be used to assess pirfenidone-induced slowing of progression of pulmonary fibrosis."
01/01/2015 - "Most recently, pirfenidone and nintedanib, two compounds with pleiotropic anti-fibrotic properties, have been proven effective in reducing functional decline and disease progression in IPF. "
08/01/2015 - "More recently, pirfenidone and nintedanib, two compounds with pleiotropic mechanisms of action, have proven effective in slowing functional decline and disease progression in IPF patients with mild to moderate functional impairment, highlighting the importance of timely diagnosis and administration of treatment in early stages of disease. "
11/19/2014 - "However, two new antifibrotic drugs, pirfenidone and nintedanib, have for the first time proven effective in slowing disease progression."
02/01/2015 - "More importantly, the period ends with the publication of two groundbreaking studies that confirmed that two drugs, pirfenidone and nintedanib, slowed disease progression, leading to a historic approval by the FDA. "
01/01/2013 - "Based upon encouraging results from randomised-controlled trials showing a positive effect in slowing decline in pulmonary function and reducing disease progression, pirfenidone was approved in 2011 as the first treatment in patients with IPF. "
|5.||Diabetic Nephropathies (Diabetic Nephropathy)
06/01/2011 - "Pirfenidone is an oral antifibrotic agent that benefits diabetic nephropathy in animal models, but whether it is effective for human diabetic nephropathy is unknown. "
01/01/2012 - "Promising agents emerging from some of the completed trials include pirfenidone and bardoxolone methyl, which have been shown in two recent randomized controlled trials in patients with diabetic nephropathy to result in an improved estimated glomerular filtration rate compared to placebo. "
01/01/2011 - "Novel, oral agents that are promising in early clinical studies are agents such as pirfenidone and bardoxolone as they are associated with early improvement in renal function in patients with advanced diabetic kidney disease. "
06/01/2011 - "In conclusion, these results suggest that pirfenidone is a promising agent for individuals with overt diabetic nephropathy."
06/01/2011 - "Pirfenidone for diabetic nephropathy."
|4.||Transforming Growth Factors (Transforming Growth Factor)
|5.||Messenger RNA (mRNA)
|7.||antiglomerular basement membrane antibody
|9.||Silicon Dioxide (Sand)
|10.||Proteins (Proteins, Gene)